S
Simon Lichtiger
Researcher at Columbia University Medical Center
Publications - 61
Citations - 8194
Simon Lichtiger is an academic researcher from Columbia University Medical Center. The author has contributed to research in topics: Ulcerative colitis & Infliximab. The author has an hindex of 26, co-authored 57 publications receiving 7475 citations. Previous affiliations of Simon Lichtiger include Columbia University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Jean-Frederic Colombel,William J. Sandborn,Walter Reinisch,Gerassimos J. Mantzaris,Asher Kornbluth,Daniel Rachmilewitz,Simon Lichtiger,Robert H. Diamond,Delma L. Broussard,Kezhen L. Tang,C. Janneke van der Woude,Paul Rutgeerts +11 more
TL;DR: Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or inflIXimab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azATHioprine monotherapy.
Journal ArticleDOI
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Simon Lichtiger,Daniel H. Present,Asher Kornbluth,Irwin M. Gelernt,Joel J. Bauer,Greg Galler,Fabrizio Michelassi,Stephen B. Hanauer +7 more
TL;DR: Intravenous cyclosporine therapy is rapidly effective for patients with severe corticosteroid-resistant ulcerative colitis.
Journal ArticleDOI
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn,Christopher Gasink,Long Long Gao,Marion Blank,Jewel Johanns,Cynthia Guzzo,Bruce E. Sands,Stephen B. Hanauer,Stephan R. Targan,Paul Rutgeerts,Subrata Ghosh,Willem J.S. de Villiers,Remo Panaccione,Gordon R. Greenberg,Stefan Schreiber,Simon Lichtiger,Brian G. Feagan +16 more
TL;DR: Patients with moderate-to-severe Crohn's disease that was resistant to TNF antagonists had an increased rate of response to induction with ustekinumab, as compared with placebo.
Journal ArticleDOI
The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease.
Adam S. Cheifetz,Asher Kornbluth,Peter Legnani,Ira Schmelkin,Alphonso Brown,Simon Lichtiger,Basil S. Lewis +6 more
TL;DR: Patients and physicians should be aware of the potential risks when using CE in CD, as a retained capsule may indicate unsuspected strictures in Crohn's that may require an unexpected, but therapeutic, surgical intervention.
Journal ArticleDOI
Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment.
TL;DR: The characteristics and risks of cancer in patients with IBD are explored, including management of IBD after a diagnosis of cancer, the effects of cancer treatment on IBD, and the effect of I BD and medications for IBD on cancer outcomes are evaluated.